Back to Search
Start Over
Different amyloid β42 preparations induce different cell death pathways in the model of SH-SY5Y neuroblastoma cells.
- Source :
-
Cellular & molecular biology letters [Cell Mol Biol Lett] 2024 Nov 17; Vol. 29 (1), pp. 143. Date of Electronic Publication: 2024 Nov 17. - Publication Year :
- 2024
-
Abstract
- Amyloid β42 (Aβ42) plays a decisive role in the pathology of Alzheimer's disease. The Aβ42 peptide can aggregate into various supramolecular structures, with oligomers being the most toxic form. However, different Aβ species that cause different effects have been described. Many cell death pathways can be activated in connection with Aβ action, including apoptosis, necroptosis, pyroptosis, oxidative stress, ferroptosis, alterations in mitophagy, autophagy, and endo/lysosomal functions. In this study, we used a model of differentiated SH-SY5Y cells and applied two different Aβ42 preparations for 2 and 4 days. Although we found no difference in the shape and size of Aβ species prepared by two different methods (NaOH or NH <subscript>4</subscript> OH for Aβ solubilization), we observed strong differences in their effects. Treatment of cells with NaOH-Aβ42 mainly resulted in damage of mitochondrial function and increased production of reactive oxygen species, whereas application of NH <subscript>4</subscript> OH-Aβ42 induced necroptosis and first steps of apoptosis, but also caused an increase in protective Hsp27. Moreover, the two Aβ42 preparations differed in the mechanism of interaction with the cells, with the effect of NaOH-Aβ42 being dependent on monosialotetrahexosylganglioside (GM1) content, whereas the effect of NH <subscript>4</subscript> OH-Aβ42 was independent of GM1. This suggests that, although both preparations were similar in size, minor differences in secondary/tertiary structure are likely to strongly influence the resulting processes. Our work reveals, at least in part, one of the possible causes of the inconsistency in the data observed in different studies on Aβ-toxicity pathways.<br />Competing Interests: Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare that they have no competing interests.<br /> (© 2024. The Author(s).)
- Subjects :
- Humans
Cell Line, Tumor
Cell Death drug effects
Alzheimer Disease metabolism
Alzheimer Disease pathology
Mitochondria metabolism
Mitochondria drug effects
Necroptosis drug effects
Oxidative Stress drug effects
Amyloid beta-Peptides metabolism
Amyloid beta-Peptides pharmacology
Neuroblastoma pathology
Neuroblastoma metabolism
Peptide Fragments pharmacology
Reactive Oxygen Species metabolism
Apoptosis drug effects
Subjects
Details
- Language :
- English
- ISSN :
- 1689-1392
- Volume :
- 29
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Cellular & molecular biology letters
- Publication Type :
- Academic Journal
- Accession number :
- 39551742
- Full Text :
- https://doi.org/10.1186/s11658-024-00657-8